A randomized, double-blind study to compare tenoxicam with sustained release indomethacin in osteoarthritic patients treated in general practice.
A total of 144 patients were recruited for this randomized, double-blind study to compare the efficacy and tolerance of tenoxicam and sustained release indomethacin in patients with osteoarthritis. The results show that 20 mg/day tenoxicam is equal in efficacy to, and significantly better tolerated than, 75 mg/day sustained release indomethacin. Patients receiving tenoxicam recorded significantly better global tolerance ratings (P = 0.042) and fewer adverse events than those receiving indomethacin.